Patrick C. Gallagher, PH.D., Attorney, Duane Morris LLP to Speak at KC’s Event
New York, NY, August 27, 2015 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today Patrick C. Gallagher, PH.D., Attorney, Duane Morris LLP will speak at the Knowledge Congress’ webcast entitled: “BPCIA Litigation: Latest Developments for 2015 and Beyond LIVE Webcast” This event is scheduled for Tuesday, September 1, 2015 @ 12:00 PM to 2:00 PM (ET).
For further details, please visit:
https://theknowledgegroup.org/event_name/bpcia-litigation-latest-developments-for-2015-and-beyond-live-webcast/
About Patrick C. Gallagher, PH.D
Mr. Gallagher focuses his practice in the area of intellectual property law with a focus on representing generic drug companies in Hatch-Waxman pharmaceutical patent litigation. Mr. Gallagher has been involved in all aspects of Hatch-Waxman practice, including advising on Abbreviated New Drug Application (ANDA) filings, development of noninfringement and invalidity arguments for FDA-required notice letters, and in every phase of litigation through trial and appeal to the Federal Circuit Court of Appeals. Admitted in Illinois and registered before the USPTO.
About Duane Morris LLP
Duane Morris LLP, a law firm with more than 700 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today’s legal and business challenges.
Evolving from a partnership of prominent lawyers in Philadelphia a century ago, Duane Morris’ modern organization stretches from the U.S. to Europe and the Middle East, and now across Asia. Throughout this global expansion, Duane Morris has remained committed to preserving its collegial, collaborative culture that has attracted many talented attorneys. The firm’s leadership, and outside observers like the Harvard Business School, believe this culture is truly unique among large law firms, and helps account for the firm continuing to prosper throughout changing economic and industry conditions.
Duane Morris lawyers hold leadership positions in bar associations, as well as in educational, cultural and charitable organizations and with community groups. Many of the firm’s attorneys come to Duane Morris after having held senior positions in government agencies and large corporations. This range of experience is further enriched by the diverse backgrounds of the firm’s attorneys. Duane Morris has long been committed to recruiting, retaining and promoting talented female and minority lawyers, many of whom hold leadership roles at the firm.
KC Event Synopsis:
Five years after the Biologics Price Competition and Innovation Act (BPCIA) has been passed into law, litigation related to the patent resolution procedure for biosimilars has begun to rise.
In a two-hour live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will offer an in-depth discussion of the significant and latest issues surrounding BPCIA. Speakers will examine the new BPCIA legal framework created to resolve patent disputes between biosimilar makers and patent holders as well the updates to recent biosimilar-related cases.
Key issues that will be covered in this course are:
- Biologics Price Competition and Innovation Act (BPCIA) – An Overview
- Latest Framework for Biosimilar Patent-Related Dispute Resolution
- Recent Developments to BPCIA Litigation such as:
- Otsuka Pharmaceutical Co., Ltd. v. FDA
- Amgen Inc. v. Sandoz Inc.
- Appeal of Amgen’s Request to Block Sales of Zarxio
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Congress is a series of live webcasts produced by The Knowledge Group, which examine trends, regulatory, and technology changes across a variety of industries. For further details, please visit: http://theknowledgegroup.org.
For further details, please visit:
https://theknowledgegroup.org/event_name/bpcia-litigation-latest-developments-for-2015-and-beyond-live-webcast/
About Patrick C. Gallagher, PH.D
Mr. Gallagher focuses his practice in the area of intellectual property law with a focus on representing generic drug companies in Hatch-Waxman pharmaceutical patent litigation. Mr. Gallagher has been involved in all aspects of Hatch-Waxman practice, including advising on Abbreviated New Drug Application (ANDA) filings, development of noninfringement and invalidity arguments for FDA-required notice letters, and in every phase of litigation through trial and appeal to the Federal Circuit Court of Appeals. Admitted in Illinois and registered before the USPTO.
About Duane Morris LLP
Duane Morris LLP, a law firm with more than 700 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today’s legal and business challenges.
Evolving from a partnership of prominent lawyers in Philadelphia a century ago, Duane Morris’ modern organization stretches from the U.S. to Europe and the Middle East, and now across Asia. Throughout this global expansion, Duane Morris has remained committed to preserving its collegial, collaborative culture that has attracted many talented attorneys. The firm’s leadership, and outside observers like the Harvard Business School, believe this culture is truly unique among large law firms, and helps account for the firm continuing to prosper throughout changing economic and industry conditions.
Duane Morris lawyers hold leadership positions in bar associations, as well as in educational, cultural and charitable organizations and with community groups. Many of the firm’s attorneys come to Duane Morris after having held senior positions in government agencies and large corporations. This range of experience is further enriched by the diverse backgrounds of the firm’s attorneys. Duane Morris has long been committed to recruiting, retaining and promoting talented female and minority lawyers, many of whom hold leadership roles at the firm.
KC Event Synopsis:
Five years after the Biologics Price Competition and Innovation Act (BPCIA) has been passed into law, litigation related to the patent resolution procedure for biosimilars has begun to rise.
In a two-hour live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will offer an in-depth discussion of the significant and latest issues surrounding BPCIA. Speakers will examine the new BPCIA legal framework created to resolve patent disputes between biosimilar makers and patent holders as well the updates to recent biosimilar-related cases.
Key issues that will be covered in this course are:
- Biologics Price Competition and Innovation Act (BPCIA) – An Overview
- Latest Framework for Biosimilar Patent-Related Dispute Resolution
- Recent Developments to BPCIA Litigation such as:
- Otsuka Pharmaceutical Co., Ltd. v. FDA
- Amgen Inc. v. Sandoz Inc.
- Appeal of Amgen’s Request to Block Sales of Zarxio
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Congress is a series of live webcasts produced by The Knowledge Group, which examine trends, regulatory, and technology changes across a variety of industries. For further details, please visit: http://theknowledgegroup.org.
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
1.800.578.4370
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Thomas LaPointe, Jr., Executive Director
1.800.578.4370
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Categories